New Patented Medicines Reported to PMPRB

Up to date as of October 15, 2021

Search by:

Keyword:

Status:

Year Reported*:

* Note: Drugs with Price Review Records linked from the brand name are only available from 2010 onward (records for 2011 will be populated over the next few months). Summary Reports are available for drug products reported prior to 2010.

Year	Company	Brand Name	Chemical Name	DIN	Therapeutic Use	Date of First Sale	Status
2019	Abbvie	Orilissa - 200 mg/tablet	elagolix	02481340	pain associated with endometriosis	24 May 2019	Within Guidelines
2019	Abbvie	Skyrizi - 75 mg/syringe	risankizumab	02487454	moderate-to-severe plaque psoriasis	13 May 2019	Within Guidelines
2019	Akcea Therapeutics Canada	Tegsedi - 284 mg/syringe	inotersen	02481383	hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)	12 Nov 2019	VCU
2019	Alnylam Pharmaceuticals, Inc.	Onpattro - 2 mg/mL	patisiran	02489252	hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)	04 Oct 2019	VCU
2019	Amgen Canada Inc.	Evenity - 105 mg/syringe	romosozumab	02489597	osteoporosis	12 Aug 2019	Within Guidelines
2019	Astrazeneca Canada Inc.	Calquence - 100 mg/capsule	acalabrutinib	02491788	cancer	02 Oct 2019	Within Guidelines
2019	Bausch Health, Canada Inc.	Vyzulta - 0.24 mg/mL	latanoprostene bunod	02484218	intraocular pressure (IOP)	17 May 2019	Within Guidelines
2019	Bayer Inc.	Vitrakvi - 20 mg/mL	larotrectinib	02490331	cancer	04 Sep 2019	Within Guidelines
2019	Bayer Inc.	Vitrakvi - 25 mg/capsule	larotrectinib	02490315	Cancer	17 Nov 2020	Under Review
2019	Biogen Canada Inc.	Spinraza - 2.4 mg/mL	nusinersen	02465663	5q Spinal Muscular Atrophy (SMA)	29 Aug 2017	Within Guidelines
2019	Biomarin Pharmaceutical Canada Inc.	Brineura - 30 mg/mL	cerliponase alfa	02484013	neuronal ceroid lipofuscinosis type 2 (CLN2)	18 Mar 2019	Within Guidelines
2019	CSL Behring Canadda Inc.	Idelvion - 1000 IU/vial	coagulation factor IX (recombinant), albumin fusion protein (RIX-FP)	02451352	hemophilia B	04 Jul 2019	Subject to Investigation
2019	Eisai Limited	Lenvima - 12 mg/day	lenvatinib mesylate	02484129	cancer	29 Oct 2019	Within Guidelines
2019	Eisai Limited	Lenvima - 4 mg/day	lenvatinib mesylate	02484056	cancer	29 Oct 2019	Within Guidelines
2019	Eli Lilly Canada Inc.	Emgality - 120 mg/mL	galcanezumab	02491060	migraine	07 Oct 2019	Subject to Investigation
2019	Eli Lilly Canada Inc.	Emgality - 120 mg/mL	galcanezumab	02491087	migraine	02 Oct 2019	Subject to Investigation
2019	Eli Lilly Canada Inc.	Verzenio - 100 mg/tablet	abemaciclib	02487101	cancer	03 Jul 2019	Within Guidelines
2019	Eli Lilly Canada Inc.	Verzenio - 150 mg/tablet	abemaciclib	02487128	cancer	03 Jul 2019	Within Guidelines
2019	Eli Lilly Canada Inc.	Verzenio - 200 mg/tablet	abemaciclib	02487136	cancer	03 Jul 2019	Within Guidelines
2019	Eli Lilly Canada Inc.	Verzenio - 50 mg/tablet	abemaciclib	02487098	cancer	03 Jul 2019	Within Guidelines
2019	Galderma Canada Inc.	Aklief - 50 mcg/gram	trifarotene	trifarot�ne	acne	28 Nov 2019	Within Guidelines
2019	Glaxosmithkline Inc.	Engerix-B - 1 N.A./dose	hepatitis B surface antigen (recombinant)	02487039	hepatitis B	18 Nov 2019	Within Guidelines
2019	Glaxosmithkline Inc.	Engerix-B Pediatric - 20 mcg/mL	hepatitis B surface antigen (recombinant)	02487020	hepatitis B	07 Oct 2019	Within Guidelines
2019	HLS Therapeutics Inc.	Vascepa - 1 g/capsule	icosapent ethyl	02495244	cardiovascular events	15 Nov 2019	Does Not Trigger Investigation
2019	Hoffman-La Roche Limited	Tecentriq - 60 mg/mL	atezolizumab	02492393	cancer	16 Oct 2019	Within Guidelines
2019	Hoffman-La Roche Limited	Actemra - 162 mg/syringe	tocilizumab	02483327	rheumatoid arthritis	15 Jan 2019	Within Guidelines
2019	Hoffman-La Roche Limited	Hemlibra - 105 mg/vial	emicizumab	02479656	hemophilia A	14 May 2019	Within Guidelines
2019	Hoffman-La Roche Limited	Hemlibra - 150 mg/mL	emicizumab	02479664	hemophilia A	14 May 2019	Within Guidelines
2019	Hoffman-La Roche Limited	Hemlibra - 60 mg/vial	emicizumab	02479648	hemophilia A	14 May 2019	Within Guidelines
2019	Hoffman-La Roche Limited	Hemlibra 30 mg/mL	emicizumab	02479621	hemophilia A	14 May 2019	Within Guidelines
2019	Ipsen Biopharmaceuticals Canada Inc.	Xermelo - 250 mg/tablet	telotristat ethyl	02481553	refractory carcinoid syndrome diarrhea	07 Dec 2018	Within Guidelines
2019	Janssen Inc.	Tremfya One-Press - 100 mg/mL	guselkumab	02487314	plaque psoriasis	21 May 2019	Within Guidelines
2019	Medexus Inc.	Metoject Subcutaneous - 10 mg/syringe	methotrexate (methotrexate sodium)	02454831	psoriasis/psoriatic arthritis and rheumatoid arthritis	01 Oct 2019	Within Guidelines
2019	Medexus Inc.	Metoject Subcutaneous - 12.5 mg/syringe	methotrexate (methotrexate sodium)	02454750	psoriasis/psoriatic arthritis and rheumatoid arthritis	01 Oct 2019	Within Guidelines
2019	Merck Canada Inc.	Delstrigo 100/300/300 - 700 mg/tablet	doravirine/lamivudine/tenofovir disoproxil fumarate	02482592	human immunodeficiency virus-1 (HIV-1)	10 Dec 2018	Within Guidelines
2019	Merck Canada Inc.	Belsomra - 10 mg/tablet	suvorexant	02483513	insomnia	18 Apr 2019	Within Guidelines
2019	Merck Canada Inc.	Belsomra - 15 mg/tablet	suvorexant	02483521	insomnia	18 Apr 2019	Within Guidelines
2019	Merck Canada Inc.	Belsomra - 20 mg/tablet	suvorexant	02483548	insomnia	18 Apr 2019	Within Guidelines
2019	Mitsubishi Tanabe Pharma Canada	Radicava - 30 mg/dose	edaravone	02475472	amyotrophic lateral sclerosis (ALS)	29 Oct 2019	Under Review
2019	Novartis Pharmaceuticals Canada Inc.	Aimovig - 140 mg/mL	erenumab	02487306	migraine	22 May 2019	VCU
2019	Novartis Pharmaceuticals Canada Inc.	Aimovig - 70 mg/mL	erenumab	02479613	migraine	04 Dec 2018	VCU
2019	Novartis Pharmaceuticals Canada Inc.	Gilenya - 0.25 mg/capsule	fingolimod hydrochloride	02482533	multiple sclerosis (MS)	03 Jan 2019	Within Guidelines
2019	Novartis Pharmaceuticals Canada Inc.	Tasigna - 50 mg/capsule	nilotinib hydrochloride monohydrate	02481715	Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)	17 May 2019	Within Guidelines
2019	Novartis Pharmaceuticals Canada Inc.	Signifor Lar - 10 mg/vial	pasireotide	02480425	acromegaly and Cushing's disease	30 May 2019	Does Not Trigger Investigation
2019	Novartis Pharmaceuticals Canada Inc.	Signifor Lar - 30 mg/vial	pasireotide	02480433	acromegaly and Cushing's disease	30 May 2019	Does Not Trigger Investigation
2019	Novartis Pharmaceuticals Canada Inc.	Kymriah - 1 N.A./dose	tisagenlecleucel	02480514	cancer	24 May 2019	Within Guidelines
2019	Novo Nordisk Canada Inc.	Xultophy - 100 unit/mL	insulin degludec/liraglutide	02474875	type 2 diabetes mellitus	15 Jun 2018	Under Review
2019	Paladin Labs Inc.	Envarsus PA - 0.75 mg/tablet	tacrolimus	02485877	prophylaxis of organ rejection	17 Apr 2019	Within Guidelines
2019	Paladin Labs Inc.	Envarsus PA - 1 mg/tablet	tacrolimus	02485885	prophylaxis of organ rejection	17 Apr 2019	Within Guidelines
2019	Paladin Labs Inc.	Envarsus PA - 4 mg/tablet	tacrolimus	02485893	prophylaxis of organ rejection	17 Apr 2019	Within Guidelines
2019	Paladin Labs Inc.	Wakix - 20 mg/tablet	pitolisant	-448	narcolepsy	30 Nov 2019	Under Review
2019	Paladin Labs Inc.	Wakix - 5 mg/tablet	pitolisant	-449	narcolepsy	30 Nov 2019	Under Review
2019	Pfizer Canada Inc.	Lorbrena - 100 mg/tablet	lorlatinib	02485974	cancer	23 Apr 2019	Within Guidelines
2019	Pfizer Canada Inc.	Lorbrena - 25 mg/tablet	lorlatinib	02485966	cancer	23 Apr 2019	Within Guidelines
2019	Pfizer Canada Inc.	Xeljanz - 10 mg/tablet	tofacitinib	02480786	rheumatoid arthritis (RA)	30 Jan 2019	Within Guidelines
2019	Pfizer Canada Inc.	Vizimpro - 15 mg/tablet	dacomitinib	02486024	cancer	23 Apr 2019	Within Guidelines
2019	Pfizer Canada Inc.	Vizimpro - 30 mg/tablet	dacomitinib	02486032	cancer	23 Apr 2019	Within Guidelines
2019	Pfizer Canada Inc.	Vizimpro - 45 mg/tablet	dacomitinib	02486040	cancer	23 Apr 2019	Within Guidelines
2019	Pfizer Canada Inc.	Xyntha Solofuse - 500 unit/syringe	moroctocog alfa	02374064	hemophilia A	01 Oct 2019	Within Guidelines
2019	Sanofi-Aventis Canada Inc.	Dupixent - 200 mg/syringe	dupilumab	02492504	atopic dermatitis	29 Nov 2019	Within Guidelines
2019	Santen SAS	Verkazia - 1 mg/mL	cyclosporine	02484137	severe vernal keratoconjunctivitis	26 Apr 2019	Within Guidelines
2019	Swedish Orphan Biovitrum, SOBI AB	Gamifant - 10 mg/vial	emapalumab		hemophagocytic lymphohistiocytosis (HLH)	30 Aug 2019	Subject to Investigation
2019	Takeda Canada Inc.	Vyvanse - 10 mg/tablet	lisdexamfetamine dimesylate	02490226	Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)	06 Aug 2019	Subject to Investigation
2019	Takeda Canada Inc.	Vyvanse - 20 mg/tablet	lisdexamfetamine dimesylate	02490234	Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)	06 Aug 2019	Subject to Investigation
2019	Takeda Canada Inc.	Vyvanse - 30 mg/tablet	lisdexamfetamine dimesylate	02490242	Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)	06 Aug 2019	Subject to Investigation
2019	Takeda Canada Inc.	Vyvanse - 40 mg/tablet	lisdexamfetamine dimesylate	02490250	Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)	06 Aug 2019	Subject to Investigation
2019	Takeda Canada Inc.	Vyvanse - 50 mg/tablet	lisdexamfetamine dimesylate	02490269	Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)	06 Aug 2019	Subject to Investigation
2019	Takeda Canada Inc.	Vyvanse - 60 mg/tablet	lisdexamfetamine dimesylate	02490277	Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)	06 Aug 2019	Subject to Investigation
2019	ThromboGenics N.V.	Jetrea - 1.25 mg/mL	ocriplasmin	02452154	vitreomacular adhesion (VMA)	08 May 2019	Within Guidelines
2019	UCB Canada Inc.	Brivlera - 10 mg/mL	brivaracetam	02452995	epilepsy	24 Jan 2019	Within Guidelines
2019	Ultragenyx Pharmaceuticals Inc.	Crysvita - 10 mg/mL	burosumab	02483629	X-linked hypophosphataemia (XLH)	28 Jan 2019	Within Guidelines
2019	Ultragenyx Pharmaceuticals Inc.	Crysvita - 20 mg/mL	burosumab	02483637	X-linked hypophosphataemia (XLH)	28 Jan 2019	Subject to Investigation
2019	Ultragenyx Pharmaceuticals Inc.	Crysvita - 30 mg/mL	burosumab	02483645	X-linked hypophosphataemia (XLH)	28 Jan 2019	Subject to Investigation
2019	Valeo Pharma	Onstryv - 100 mg/tablet	safinamide	02484668	Parkinson's disease	08 Jul 2019	Within Guidelines
2019	Valeo Pharma	Onstryv - 50 mg/tablet	safinamide	02484641	Parkinson's disease	08 Jul 2019	Within Guidelines
2019	Verity Pharmaceuticals Inc.	Zeulide Depot - 22.5 mg/vial	leuprolide acetate	02462699	cancer	08 Oct 2019	Subject to Investigation
2019	Verity Pharmaceuticals Inc.	Zeulide Depot - 3.75 mg/dose	leuprolide acetate	02429977	cancer	08 Oct 2019	Subject to Investigation
2019	Vertex Pharmaceuticals Canada Inc.	Orkambi 100/125 - 225 mg/granule	lumacaftor/ivacaftor	02483831	cystic fibrosis (CF) and homozygous for the F508del mutation	14 Dec 2018	Under Review
2019	Vertex Pharmaceuticals Canada Inc.	Orkambi 150/188 - 338 mg/granule	lumacaftor/ivacaftor	02483858	cystic fibrosis (CF) and homozygous for the F508del mutation	14 Dec 2018	Under Review
2019	Vifor International AG	Velphoro - 500 mg/tablet	iron (sucroferric oxyhydroxide)	02471574	renal disease	20 Nov 2019	Does Not Trigger Investigation
2019	Vifor International AG	Veltassa - 16.8 g/sachet	patiromer	02481367	kidney disease	27 Nov 2019	Subject to Investigation
2019	Viiv Healthcare Ulc	Dovato 50/300 - 350 mg/tablet	dolutegravir/lamivudine	02491753	HIV	11 Sep 2019	Within Guidelines

Language selection

Search and menus

Search

New Patented Medicines Reported to PMPRB

Search by: